Follow-up: Amarex Keynotes at GLORIA NCKU | November 29, 2019, Tainan City, Taiwan

On 29 November 2019, at the Global Research & Industry Alliance of National Cheng-Kung University (GLORIA NCKU) in Tainan City, Taiwan, Dr. Kazem Kazempour, President & CEO of Amarex, keynoted on the topic of Current Regulatory Thinking on AI/ML as SaMDs.

19 December 2019
BIO-Europe (1).png

November 2019 Conference Activities and Networking Opportunities in Europe

Amarex is pleased to announce that it will participate in two fast-approaching partnership opportunities in Europe: BIO-Europe Fall 2019 and the Lunch and Learn: Health Sciences’ Industry Updates seminar hosted by NSF International, Amarex’s partner company.

29 October 2019

Amarex to Exhibit at the DIA/FDA Oligonucleotide-Based Therapeutics Conference | October 28-30, 2019, North Bethesda, MD

This conference connects experts within the field of Oligonucleotide-based therapeutics and provides attendees the opportunity to learn about the latest industry advances and challenges.

25 October 2019

Investment by NSF International in Amarex

Amarex Clinical Research, LLC is pleased to announce that global public health organization NSF International has made majority investment in Amarex.

09 October 2019

As a full-service, international CRO, Amarex Clinical Research has extensive experience successfully performing clinical studies across all phases of research and discovery, development, validation and approval.​​​

Recommended by the people who matter most: our clients.


Chief Medical Officer 

A Maryland Biotech Company

We have worked with Amarex on numerous projects and they consistently deliver high quality reliable service by leveraging a broad array of clinical and regulatory expertise. What sets them apart from other CROs is a creative entrepreneurial approach to drug development. They go beyond the technical aspects of clinical trial development and work with the sponsor to drive value and increase chances for success.



Chief Technical Officer

A Canadian-based Infectious Diseases Organization

[Thank you to the team at Amarex] for the statistical support which proved to be invaluable and completely accurate in the final review by FDA. The cornerstone of this milestone achievement was the data from the clinical study, including the limit of detection study, and we came through [all FDA reviews with solid outcomes throughout]. From all of us here, a sincere thank you and well done to all at Amarex who worked on this project. We look forward to working with you again as we apply the successful platform to other diagnostic device developments in the future.



  • Facebook Social Icon
  • Twitter Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon


           © 2019 Amarex Clinical Research, LLC. All rights reserved.                                                                                                                                                                                                                                                   Top of Page 

Contact     Privacy Policy     Clinical Site Registration     WebView

NSF Mark_100x100.jpg